The reimbursement of COVID-19 PCR testing to be reduced in Germany

26

Jun 2020

The reimbursement for PCR tests for the detection of SARS-CoV-2 will be reduced from €59.00 to €39.40 per test beginning from July 1, 2020, and the billing of the examination will be limited to five times in the case of treatment. This decision was made by the extended evaluation committee on June 10, 2020.

The laboratory test for SARS-CoV-2 can be performed and calculated by specialists for laboratory medicine or microbiology, virology, and infectious disease epidemiology.

For this purpose, a new fee order item (GOP) was added to the EBM on February 1, 2020: 32816 “Detection of the beta-coronavirus SARS-CoV-2 nucleic acid using RT-PCR including a confirmation test for reactivity in the search test (report of findings within 24 hours after submission of material)” (Nukleinsäurenachweis des beta-Coronavirus SARS-CoV-2 mittels RT-PCR einschließlich eines Bestätigungstestes bei Reaktivität im Suchtest (Befundmitteilung innerhalb von 24 Stunden nach Materialeinsendung)). The GOP 32816 was previously valued at €59.00 per PCR test and will now be reduced to €39.40 starting from July 1, 2020. Costs for the material shipping and transporting can be calculated in addition to other special laboratory services.

The cost of the PCR test when billing according to the fee schedule for doctors (GOÄ) stays unchanged and amounts ca. €120.

The full details in German can be found here.

The full list of COVID-19 tests presented on the German market as of June 12, 2020, can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more